Results 211 to 220 of about 39,960 (300)

Structural Basis for D3/D4-Selective Antagonism of Piperazinylalkyl Pyrazole/Isoxazole Analogs. [PDF]

Molecules
Choi KE, Jang SH, Park WK, No KT, Koh HY, Pae AN, Cho NC.   +6 more
europepmc   +1 more source

Chemoselective Diazine Dearomatization: The Catalytic Enantioselective Dearomatization of Pyrazine. [PDF]

J Am Chem Soc
Ketelboeter DR, Pappoppula M, Aponick A.
europepmc   +1 more source

Brief Report: Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results From IMPAACT 2010/VESTED. [PDF]

J Acquir Immune Defic Syndr
Nguyen T, Chae JW, Ziemba L, Coletti A, Knowles K, Johnston B, Jean-Philippe P, Mhembere T, Chawana T, Wabwire D, Korutaro V, Moyo S, Mandima P, Sibisi S, Violari A, Hanley S, Mmbaga B, Masheto G, Ponatshego P, Theron G, Naik SN, Shapiro R, Lockman S, Chinula L, Momper JD, IMPAACT 2010/VESTED Protocol Team.   +25 more
europepmc   +1 more source

Non-imidazole histamine H ligands: part V. synthesis and preliminary pharmacological investigation of 1-[2-thiazol-4-yl- and 1-[2-thiazol-5-yl-(2-aminoethyl)]-4--propylpiperazine derivatives [PDF]

core   +1 more source

Distribution and efficacy of dolutegravir-based regimens in the main HIV outpatient care in Caracas, Venezuela. [PDF]

AIDS Res Ther
Alvarado-Bruzual MF, Mendoza-Merlo VA, Martinez-Torres JA, Guerra-Reyes LJ, Guevara RN, Carballo M, Redondo MC, Landaeta ME, Forero-Peña DA.   +8 more
europepmc   +1 more source

Multitargeted Aza-Arylcarboxamides for Neurodegenerative Diseases: Potent Histamine H₃ Receptor Ligands with Anticholinesterase and Metal-Chelating Activities. [PDF]

ACS Chem Neurosci
Lopes FB, Werner T, Bagatin IA, Stark H, Fernandes JPS.   +4 more
europepmc   +1 more source

Patient-derived organoids based on targeted biopsy of primary prostate cancer: development, identification, and drug screening. [PDF]

Ann Med
Qian J, Peng S, Gao J, Fu Y, Huang H, Wu C, Gan W, Qiu X, Guo H.   +8 more
europepmc   +1 more source

Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells. [PDF]

Sci Rep
Roehrle J, Perugachi-Heinsohn A, Gatzemeier F, Christiansen S, Petersen C, Rothkamm K, Betz C, Kriegs M, Zech HB, Rieckmann T.   +9 more
europepmc   +1 more source

Palbociclib in Combination with Endocrine Therapy in Patients with Metastatic Breast Cancer in a Real-World Population: Impact of Dose-Intensity, Dose Reductions and Cycle Delays on Efficacy. [PDF]

Curr Oncol
Coussirou J, Grenier J, Mege A, Arnaud A, De Crozals F, Bonnet E, Vazquez L.   +6 more
europepmc   +1 more source